Vichien Srimuninnimit

Researcher Next ID · RN-012960

Researcher · Medicine

, Thailand

Not currently recruitingFunding unknown

Research interests

Medicine

Biochemistry, Genetics and Molecular Biology

Lung Cancer Treatments and Mutations

Cancer Treatment and Pharmacology

Colorectal Cancer Treatments and Studies

Advanced Breast Cancer Therapies

Breast Cancer Treatment Studies

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
The Lancet · 2019 · 10.1016/s0140-6736(18)32409-7
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)00163-7
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Clinical Cancer Research · 2015 · 10.1158/1078-0432.ccr-14-2594
Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
Journal of Clinical Oncology · 2014 · 10.1200/jco.2013.54.6911
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
The Lancet Oncology · 2011 · 10.1016/s1470-2045(11)70336-9

No projects listed.